A detailed history of Group One Trading, L.P. transactions in Nektar Therapeutics stock. As of the latest transaction made, Group One Trading, L.P. holds 27,138 shares of NKTR stock, worth $25,238. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,138
Previous 29,738 8.74%
Holding current value
$25,238
Previous $36,000 2.78%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.11 - $1.48 $2,886 - $3,848
-2,600 Reduced 8.74%
27,138 $35,000
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $9,250 - $18,808
10,278 Added 52.82%
29,738 $36,000
Q1 2024

May 10, 2024

BUY
$0.49 - $0.96 $9,535 - $18,681
19,460 New
19,460 $18,000
Q1 2022

May 12, 2022

SELL
$4.16 - $13.72 $643,331 - $2.12 Million
-154,647 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$10.83 - $18.41 $65,250 - $110,920
6,025 Added 4.05%
154,647 $2.09 Million
Q3 2021

Nov 12, 2021

BUY
$13.07 - $18.84 $188,181 - $271,258
14,398 Added 10.73%
148,622 $2.67 Million
Q2 2021

Aug 10, 2021

SELL
$16.52 - $20.4 $198,107 - $244,636
-11,992 Reduced 8.2%
134,224 $2.3 Million
Q1 2021

May 12, 2021

SELL
$16.56 - $25.46 $101,943 - $156,731
-6,156 Reduced 4.04%
146,216 $2.92 Million
Q4 2020

Feb 10, 2021

BUY
$15.77 - $19.03 $85,284 - $102,914
5,408 Added 3.68%
152,372 $2.59 Million
Q3 2020

Nov 12, 2020

SELL
$16.59 - $24.79 $149,326 - $223,134
-9,001 Reduced 5.77%
146,964 $2.44 Million
Q2 2020

Aug 13, 2020

BUY
$16.86 - $23.44 $553,699 - $769,793
32,841 Added 26.67%
155,965 $3.61 Million
Q1 2020

May 13, 2020

SELL
$14.47 - $27.96 $2.79 Million - $5.39 Million
-192,604 Reduced 61.0%
123,124 $2.2 Million
Q4 2019

Feb 10, 2020

BUY
$15.87 - $23.12 $594,188 - $865,635
37,441 Added 13.45%
315,728 $6.82 Million
Q3 2019

Nov 12, 2019

BUY
$16.91 - $36.27 $3.7 Million - $7.93 Million
218,613 Added 366.35%
278,287 $5.07 Million
Q2 2019

Aug 09, 2019

BUY
$31.0 - $36.3 $645,234 - $755,548
20,814 Added 53.56%
59,674 $2.12 Million
Q1 2019

May 13, 2019

SELL
$31.58 - $46.35 $1.02 Million - $1.5 Million
-32,435 Reduced 45.49%
38,860 $1.31 Million
Q4 2018

Feb 06, 2019

SELL
$30.43 - $56.65 $1.6 Million - $2.99 Million
-52,731 Reduced 42.52%
71,295 $2.34 Million
Q3 2018

Nov 08, 2018

SELL
$46.46 - $68.49 $5.49 Million - $8.09 Million
-118,160 Reduced 48.79%
124,026 $7.56 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $4.76 Million - $10.8 Million
102,950 Added 73.94%
242,186 $11.8 Million
Q1 2018

May 11, 2018

BUY
$57.4 - $108.44 $1.51 Million - $2.86 Million
26,393 Added 23.39%
139,236 $14.8 Million
Q4 2017

Feb 09, 2018

BUY
$23.02 - $60.5 $2 Million - $5.25 Million
86,811 Added 333.48%
112,843 $6.74 Million
Q3 2017

Nov 15, 2017

SELL
$17.79 - $24.0 $522,581 - $705,000
-29,375 Reduced 53.02%
26,032 $625,000
Q2 2017

Aug 14, 2017

BUY
N/A
55,407
55,407 $1.08 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.